中国卫生资源
中國衛生資源
중국위생자원
CHINESE HEALTH RESOURCES
2014年
4期
277-280
,共4页
宋圣帆%叶露%胡善联%杜丽侠%施强
宋聖帆%葉露%鬍善聯%杜麗俠%施彊
송골범%협로%호선련%두려협%시강
肺炎链球菌病%住院患者%医疗费用
肺炎鏈毬菌病%住院患者%醫療費用
폐염련구균병%주원환자%의료비용
pneumococcal disease%inpatient%medical cost
目的:了解上海肺炎链球菌病住院患者患病情况并分析上海地区侵袭性肺炎链球菌病的医疗费用情况和影响因素。方法:通过查阅文献、上海地区人口学数据、相关文献和政策资料,收集上海地区全年龄段人群在侵袭性肺炎链球菌病(脑膜炎,菌血症和肺炎)的住院医疗费用数据,结合上海地区人口学进行统计和分析。结果:2011年上海地区全年共有27723例肺炎住院患者、250例脑膜炎住院患者纳入研究,肺炎和脑膜炎患者的平均住院日为13.00d和22.63d,住院次均总费用为10971元和23322元,其中药占比较高,在肺炎和脑膜炎治疗费用中均超过了50%。结论:我国应当进一步推进临床路径试点,规范肺炎链球菌病的诊疗流程,控制药品的合理使用。
目的:瞭解上海肺炎鏈毬菌病住院患者患病情況併分析上海地區侵襲性肺炎鏈毬菌病的醫療費用情況和影響因素。方法:通過查閱文獻、上海地區人口學數據、相關文獻和政策資料,收集上海地區全年齡段人群在侵襲性肺炎鏈毬菌病(腦膜炎,菌血癥和肺炎)的住院醫療費用數據,結閤上海地區人口學進行統計和分析。結果:2011年上海地區全年共有27723例肺炎住院患者、250例腦膜炎住院患者納入研究,肺炎和腦膜炎患者的平均住院日為13.00d和22.63d,住院次均總費用為10971元和23322元,其中藥佔比較高,在肺炎和腦膜炎治療費用中均超過瞭50%。結論:我國應噹進一步推進臨床路徑試點,規範肺炎鏈毬菌病的診療流程,控製藥品的閤理使用。
목적:료해상해폐염련구균병주원환자환병정황병분석상해지구침습성폐염련구균병적의료비용정황화영향인소。방법:통과사열문헌、상해지구인구학수거、상관문헌화정책자료,수집상해지구전년령단인군재침습성폐염련구균병(뇌막염,균혈증화폐염)적주원의료비용수거,결합상해지구인구학진행통계화분석。결과:2011년상해지구전년공유27723례폐염주원환자、250례뇌막염주원환자납입연구,폐염화뇌막염환자적평균주원일위13.00d화22.63d,주원차균총비용위10971원화23322원,기중약점비교고,재폐염화뇌막염치료비용중균초과료50%。결론:아국응당진일보추진림상로경시점,규범폐염련구균병적진료류정,공제약품적합리사용。
Objective:To analyze inpatients’ direct medical costs of pneumococcal diseases and their influencing factors in Shanghai. Methods:Systematic sampling was used to collect data on direct medical costs of inpatients with pneumococcal diseases and relevant statistics methods were used to analyze the data combining with health statistical yearbook. Results:There were 27 723 cases of pneumonia and 250 cases of meningitis in Shanghai in 2011 and no case of bacteremia was found. The average length of hospital stay was 13.00 days and 22.63 days for pneumonia and meningitis,respectively. The hospitalization expense of pneumonia and meningitis was 10 971 yuan and 23 322 yuan,respectively. Drug cost was an important part of pneumonia treatment,which counted more than 50%of the total expense. Conclusion:The government needs to further promote the pilot on clinical pathway,standardize the process of diagnosis and treatment of pneumococcal diseases and control rational use of pharmaceuticals.